Preclinical and Coclinical Studies in Prostate Cancer.
Abstract
Men who develop metastatic castration-resistant prostate cancer (mCRPC) will invariably
succumb to their disease. Thus there remains a pressing need for preclinical testing
of new drugs and drug combinations for late-stage prostate cancer (PCa). Insights
from the mCRPC genomic landscape have revealed that, in addition to sustained androgen
receptor (AR) signaling, there are other actionable molecular alterations and distinct
molecular subclasses of PCa; however, the rate at which this knowledge translates
into patient care via current preclinical testing is painfully slow and inefficient.
Here, we will highlight the issues involved and discuss a new translational platform,
"the co-clinical trial project," to expedite current preclinical studies and optimize
clinical trial and experimental drug testing. With this platform, in vivo preclinical
and early clinical studies are closely aligned, enabling in vivo testing of drugs
using genetically engineered mouse models (GEMMs) in defined genetic contexts to personalize
individual therapies. We will discuss the principles and essential components of this
novel paradigm, representative success stories and future therapeutic options for
mCRPC that should be explored.
Type
Journal articleSubject
AnimalsHumans
Mice
Disease Models, Animal
Receptors, Androgen
Antineoplastic Combined Chemotherapy Protocols
Drug Resistance, Neoplasm
Male
Clinical Trials as Topic
Prostatic Neoplasms, Castration-Resistant
Antineoplastic Agents, Immunological
Permalink
https://hdl.handle.net/10161/20377Published Version (Please cite this version)
10.1101/cshperspect.a030544Publication Info
Chen, Ming; & Pandolfi, Pier Paolo (2018). Preclinical and Coclinical Studies in Prostate Cancer. Cold Spring Harbor perspectives in medicine, 8(4). pp. a030544-a030544. 10.1101/cshperspect.a030544. Retrieved from https://hdl.handle.net/10161/20377.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Ming Chen
Associate Professor in Pathology
Our laboratory is interested in understanding the molecular and genetic events underlying
cancer progression and metastasis. The focus of our work is a series of genetically
engineered mouse models that faithfully recapitulate human disease. Using a combination
of mouse genetics, omics technologies, cross-species analyses and in vitro approaches,
we aim to identify cancer cell–intrinsic and –extrinsic mechanisms driving
metastatic cancer progression, with a long

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info